Observational studyEuropean journal of clinical pharmacology2023

Alogliptin: a DPP-4 inhibitor modulating adipose tissue insulin resistance and atherogenic lipid.

Eiji Kutoh et al.PubMed ↗Publisher ↗

No numbers read from the abstract.